<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="topic" /><meta name="keywords" content="Osteoporosis; Osteoporosis: calcium; Osteoporosis: postmenopausal; Osteoporosis: HRT; Hormone replacement: osteoporosis; Bisphosphonates: osteoporosis; Alendronic acid; Disodium etidronate; Risedronate sodium; Osteoporosis: bisphosphonates; Osteoporosis: calcitriol; Osteoporosis: strontium ranelate; Strontium ranelate; Calcitonin; Osteoporosis: calcitonin; Teriparatide; Osteoporosis: teriparatide; Parathyroid hormone; Osteoporosis: parathyroid hormone; Raloxifene; Osteoporosis: raloxifene; Osteoporosis: corticosteroid-induced" /><meta name="IX" content="Osteoporosis; Osteoporosis: calcium; Osteoporosis: postmenopausal; Osteoporosis: HRT; Hormone replacement: osteoporosis; Bisphosphonates: osteoporosis; Alendronic acid; Disodium etidronate; Risedronate sodium; Osteoporosis: bisphosphonates; Osteoporosis: calcitriol; Osteoporosis: strontium ranelate; Strontium ranelate; Calcitonin; Osteoporosis: calcitonin; Teriparatide; Osteoporosis: teriparatide; Parathyroid hormone; Osteoporosis: parathyroid hormone; Raloxifene; Osteoporosis: raloxifene; Osteoporosis: corticosteroid-induced" /><title>Osteoporosis: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="100042.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="100042.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=100042.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2073.htm">6 Endocrine system</a> &gt; <a href="4439.htm">6.6 Drugs affecting bone metabolism</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4439.htm" title="Previous: 6.6 Drugs affecting bone metabolism">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="4440.htm" title="Next: 6.6.1 Calcitonin and parathyroid hormone">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_100042">Osteoporosis</h1><?highlighter on?><div id="pC" class="jN"><p>Osteoporosis
occurs most commonly in postmenopausal women and in those taking long-term
oral <span>corticosteroids</span> (glucocorticosteroids). Other
risk factors for osteoporosis include low body weight, cigarette smoking,
excess <span>alcohol</span> intake, lack of physical activity,
family history of osteoporosis, and early menopause.</p><div class="cN"><p>Those at risk of osteoporosis should maintain an adequate
intake of <b>calcium and vitamin D</b> and any deficiency should
be corrected by increasing dietary intake or taking supplements.</p></div><p>Elderly patients, especially those who are housebound or live
in residential or nursing homes, are at increased risk of calcium
and vitamin D deficiency and may benefit from supplements (<a title=" Calcium supplements" href="5030.htm#_5030">section 9.5.1.1</a> and <a title=" Vitamin D" href="5130.htm#_5130">section
9.6.4</a>). Reversible secondary causes of osteoporosis such as
hyperthyroidism, hyperparathyroidism, osteomalacia or hypogonadism
should be excluded, in both men and women, before treatment for osteoporosis
is initiated.</p><div id="_100042.1"><div class="cAZ"><h2>Postmenopausal osteoporosis</h2> <p class="cAX">The <b><span>bisphosphonates</span></b> (alendronic acid, disodium etidronate, and risedronate, <a title=" Bisphosphonates" href="4446.htm#_4446">section 6.6.2</a>) are effective for preventing postmenopausal
osteoporosis. <b>Hormone replacement therapy</b> (HRT <a title=" Oestrogens and HRT" href="4299.htm#_4299">section 6.4.1.1</a>) is an option where other therapies are contra-indicated,
cannot be tolerated, or if there is a lack of response. The CSM has
advised that HRT should <b>not</b> be considered first-line
therapy for long-term prevention of osteoporosis in women over 50
years of age. HRT is of most benefit for the prophylaxis of postmenopausal
osteoporosis if started early in menopause and continued for up to
5 years, but bone loss resumes (possibly at an accelerated rate) on
stopping HRT. <b>Calcitonin </b>(<a title=" Calcitonin" href="4440.htm#_4440">section
6.6.1</a>) may be considered for those at high risk of osteoporosis
for whom a bisphosphonate is unsuitable. Women of Afro-Caribbean origin appear
to be less susceptible to osteoporosis than those who are white or
of Asian origin.</p><p>Postmenopausal osteoporosis may be <i>treated</i> with
a <b>bisphosphonate</b> (<a title=" Bisphosphonates" href="4446.htm#_4446">section 6.6.2</a>). The <span>bisphosphonates</span> (such
as alendronate, etidronate, and risedronate) decrease the risk of
vertebral fracture; alendronate and risedronate have also been shown
to reduce non-vertebral fractures. If bisphosphonates are unsuitable <b><span>calcitriol</span></b> (<a title=" Vitamin D" href="5130.htm#_5130">section
9.6.4</a>), <b>calcitonin</b> or <b><span>strontium
ranelate</span></b> (<a title="BNF:monograph-family: Strontium ranelate" href="129618.htm#_129618">section 6.6.2</a>) may be considered. Calcitonin [unlicensed indication] may also
be useful for pain relief for up to 3 months after a vertebral fracture
if other <span>analgesics</span> are ineffective. <b>Parathyroid hormone</b>, and <b>teriparatide</b> (<a title="sub-section: Calcitonin" href="4440.htm#_4440">section 6.6.1</a>) have been introduced for the treatment of postmenopausal
osteoporosis.</p><p><b>Raloxifene</b> (<a title=" Oestrogens and HRT" href="4299.htm#_4299">section 6.4.1.1</a>) is licensed for the <i>prophylaxis</i> and <i>treatment</i> of vertebral fractures in postmenopausal
women.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Alendronate, etidronate, risedronate, raloxifene
and strontium ranelate for the primary prevention of osteoporotic
fragility fractures in postmenopausal women (October 2008)</h3><p><b>Alendronate</b> is recommended as a treatment option
for the primary prevention of osteoporotic fractures in the following
susceptible postmenopausal women: </p><ul class="cBF"><li><p class="cQ">Women over 70 years who have an independent risk factor
for fracture (parental history of hip fracture, alcohol intake of
4 or more units per day, or rheumatoid arthritis) <i>or</i> an indicator of low bone mineral density (body mass index under
22 kg/m<sup>2</sup>, ankylosing spondylitis, Crohn’s disease, prolonged
immobility, untreated premature menopause, or rheumatoid arthritis) <b>and</b> confirmed osteoporosis</p></li><li><p class="cQ">Women aged 65–69 years who have an independent risk factor
for fracture <b>and</b> confirmed osteoporosis</p></li><li><p class="cQ">Women under 65 years who have an independent risk factor
for fracture <b>and</b> at least one additional indicator
of low bone mineral density <b>and</b> confirmed osteoporosis</p></li></ul><p><b>Risedronate</b> or <b>etidronate</b> are
recommended as alternatives for women:</p><ul class="cBF"><li><p class="cQ">in whom alendronate is contra-indicated or not tolerated <b>and</b></p></li><li><p class="cQ">who comply with particular combinations of bone mineral
density measurement, age, and independent risk factors for fracture,
as indicated in the full NICE guidance<sup class="footnote"><a title="Go to footnote" href="100042.htm#footnote201701">(1)</a></sup></p></li></ul><p><b>Strontium ranelate</b> is recommended as an alternative
for women:</p><ul class="cBF"><li><p class="cQ">in whom alendronate and either risedronate or editronate
are contra-indicated or not tolerated <b>and</b></p></li><li><p class="cQ">who comply with particular combinations of bone mineral
density measurement, age, and independent risk factors for fracture,
as indicated in the full NICE guidance<sup class="footnote"><a title="Go to footnote" href="100042.htm#footnote201701">(1)</a></sup></p></li></ul><p><b>Raloxifene</b> is <b>not</b> recommended
as a treatment option in postmenopausal women for primary prevention
of osteoporotic fractures.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Alendronate, etidronate, risedronate, raloxifene,
strontium ranelate, and teriparatide for the secondary prevention
of osteoporotic fragility fractures in postmenopausal women (October
2008)</h3><p>This guideline recommends treatment options for the secondary
prevention of osteoporotic fractures in postmenopausal women with
confirmed osteoporosis who have also sustained a clinically apparent
osteoporotic fracture.</p><p><b>Alendronate</b> is recommended as a treatment option
for the secondary prevention of osteoporotic fractures in susceptible
postmenupausal women.</p><p><b>Risedronate</b> or <b>etidronate</b> are
recommended as alternatives for women:</p><ul class="cBF"><li><p class="cQ">in whom alendronate is contra-indicated or not tolerated <b>and</b> </p></li><li><p class="cQ">who comply with particular combinations of bone mineral
density measurement, age, and independent risk factors for fracture
(parental history of hip fracture, alcohol intake of 4 or more units
per day, or rheumatoid arthritis, as indicated in the full NICE guidance<sup class="footnote"><a title="Go to footnote" href="100042.htm#footnote201716">(2)</a></sup></p></li></ul><p><b>Strontium ranelate</b> or <b>raloxifene</b> are recommended as alternatives for women:</p><ul class="cBF"><li><p class="cQ">in whom alendronate and either risedronate or editronate
are contra-indicated or not tolerated <b>and</b></p></li><li><p class="cQ">who comply with particular combinations of bone mineral
density measurement, age, and independent risk factors for fracture,
as indicated in the full NICE guidance<sup class="footnote"><a title="Go to footnote" href="100042.htm#footnote201716">(2)</a></sup></p></li></ul><p><b>Teriparatide</b> is recommended as an alternative
for women:</p><ul class="cBF"><li><p class="cQ">in whom alendronate and either risedronate or editronate, <i>or</i> strontium ranelate are contra-indicated or not tolerated, <b>or</b> where treatment with alendronate, risedronate or editronate
has been unsatisfactory (indicated by another fragility fracture and
a decline in bone mineral density despite treatment for 1 year) <b>and</b> </p></li><li><p class="cQ">who comply with particular combinations of bone mineral
density measurement, age, and number of fractures, as indicated in
the full NICE guidance<sup class="footnote"><a title="Go to footnote" href="100042.htm#footnote201716">(2)</a></sup></p></li></ul></div></div><div class="cAZ"><h2>Corticosteroid-induced osteoporosis</h2> <p class="cAX">To reduce
the risk of osteoporosis doses of oral <span>corticosteroids</span> should be as low as possible and courses of treatment as short as
possible. The risk of osteoporosis may be related to cumulative dose
of corticosteroids; even intermittent courses can therefore increase
the risk. The greatest rate of bone loss occurs during the first 6–12
months of corticosteroid use and so early steps to prevent the development
of osteoporosis are important. Long-term use of high-dose inhaled
corticosteroids may also contribute to corticosteroid-induced osteoporosis
(<a title="section: Corticosteroids" href="2985.htm#_2985">section 3.2</a>).</p><p>Patients taking (or who are likely to take) an oral corticosteroid
for 3 months or longer should be assessed and where necessary given
prophylactic treatment; those aged over 65 years are at greater risk.
Patients taking oral <span>corticosteroids</span> who have sustained
a low-trauma fracture should receive treatment for osteoporosis. The
therapeutic options for <i>prophylaxis</i> and <i>treatment</i> of corticosteroid-induced osteoporosis are the same:</p><ul class="cBF"><li><p class="cQ">a bisphosphonate (<a title="BNF:monograph-family: Bisphosphonates" href="129617.htm#_129617">section 6.6.2</a>);</p></li><li><p class="cQ"><span>calcitriol</span> [unlicensed indication]
(<a title="BNF:monograph: CALCITRIOL" href="5141.htm#_5141">section 9.6.4</a>);</p></li><li><p class="cQ">hormone replacement (HRT in women (<a title="topic: Hormone replacement therapy" href="100039.htm#_100039">section 6.4.1</a>), testosterone in men [unlicensed
indication] (<a title="monograph: TESTOSTERONE AND ESTERS" href="4361.htm#_4361">section 6.4.2</a>)).</p></li></ul></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4439.htm">Previous: 6.6 Drugs affecting bone metabolism</a> | <a class="top" href="100042.htm#">Top</a> | <a accesskey="]" href="4440.htm">Next: 6.6.1 Calcitonin and parathyroid hormone</a> ►</div><div class="cF"><div class="footnote" id="footnote201701"><sup>(1)</sup>Available at <a href="http://www.nice.org.uk/TA160" title="external link">www.nice.org.uk/TA160</a></div><div class="footnote" id="footnote201716"><sup>(2)</sup>Available at <a href="http://www.nice.org.uk/TA161" title="external link">www.nice.org.uk/TA161</a></div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>